Business
Zomedica Announces First Quarter 2025 Financial Results: Revenue of $6.5 Million; 68% Gross Margin, and $65 Million in Liquidity to Support Growth
Zomedica Announces First Quarter 2025 Financial Results: Revenue of $6.5 Million; 68% Gross Margin, and $65 Million in Liquidity to Support Growth.
About this update from Zomedica Corp.
[{"type":"text","content":"\r\n\r\n \r\n \r\n Zomedica Announces First Quarter 2025 Financial Results: Revenue of $6.5 Million; 68% Gross Margin, and $65 Million in Liquidity to Support Growth\r\n \r\n \r\n\r\n\r\nZomedica Announces First Quarter 2025 Financial Results: Revenue of $6.5 Million; 68% Gross Margin, and $65 Million in Liquidity to Support Growth\r\n\r\n\r\n\r\n\r\n\r\nANN ARBOR, MI / ACCESS Newswire / May 15, 2025 / Zomedica Corp. (OTCQB:ZOMDF) (\"Zomedica\" or the \"Company\"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today reported consolidated financial results for the first quarter ended March 31, 2025.\r\n \"We are pleased with our performance in the first quarter as we posted record year over year revenue for the 17th straight quarter,\" said Larry Heaton, President and Chief Executive Officer of Zomedica. \"Bolstered by continued and robust usage of our consumable PulseVet® products, and the continued growth and adoption of our TRUFORMA® products, we were able to deliver the strongest first quarter in company history.\r\n \"Through further expansion of our portfolio, highlighted by the introduction of our new VETIGEL® product line, and the continued optimization of our commercial organization, we are seeing the positive impact in both placements and consumable usage, further supporting a foundation for recurring sales revenue in the future.\r\n \"International sales continue to grow, with sales up 32% compared to the first quarter of 2024, driven by a combination of organic growth and orders from new distributor partners. Gross margin, a key component of reaching profitability, came in at 68% compared to 66% in the first quarter of 2024.\r\n \"Based on the momentum we have created through the first quarter of the year, supported by the strength of our balance sheet, we believe that we are well positioned to aggressively execute on our strategy to drive the accelerated adoption of our innovative portfolio on a global scale,\" concluded Mr. Heaton.\r\n 2025 First Quarter Financial Highlights\r\n Revenue for the first quarter of 2025 grew by 4% to $6.5 million, compared to first quarter 2024 revenue, highlighted by 13% growth in the sale of Consumables, driven primarily by accelerating adoption of our TRUFORMA line of products and the continued,...